Kaleido Biosciences (NASDAQ:KLDO) posted its earnings results on Thursday. The company reported ($0.83) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.74) by ($0.09), Bloomberg Earnings reports.
Shares of KLDO stock traded down $0.32 on Friday, reaching $7.21. The stock had a trading volume of 27,391 shares, compared to its average volume of 31,618. Kaleido Biosciences has a 1 year low of $7.01 and a 1 year high of $19.00. The stock’s 50 day simple moving average is $10.05.
KLDO has been the subject of a number of research analyst reports. Zacks Investment Research raised Kaleido Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday, July 3rd. Chardan Capital started coverage on Kaleido Biosciences in a research note on Tuesday, April 23rd. They issued a “buy” rating and a $17.50 price target on the stock. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Kaleido Biosciences currently has an average rating of “Buy” and an average target price of $17.70.
Kaleido BioSciences, Inc develops microbiome metabolic therapies. It offers treatment for hyperammonemia, a metabolic condition generally characterized by elevated levels of ammonia in the blood; infections caused by multi-drug resistant bacteria; chronic kidney disease; atherosclerotic cardiovascular disease; and drug or disease induced diarrhea.
Recommended Story: How to use beta for portfolio diversification
Receive News & Ratings for Kaleido Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kaleido Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.